SNBL USA appoints vp of business development

Mark Crane takes overall responsibility for marketing, sales and business development

SNBL USA, a provider of preclinical services, has announced the arrival of Mark Crane as vice president of business development.

Crane takes responsibility for the company’s marketing, sales and business development efforts. He joins SNBL USA from Ricerca Biosciences where he was vice president of global sales and marketing.

Crane has held similar positions at Bridge Pharmaceutical (formerly GeneLogic), Quest Pharmaceutical Services, and MDS Pharma Services.

SNBL USA is a subsidiary of Shin Nippon Biomedical Laboratories (SNBL), one of the largest CROs in Japan.

You may also like

Research & Development

PPD and SNBL form JV to provide clinical development services in Japan

Will combine PPD's clinical development operations in Japan with SNBL's clinical research division
Research & Development
Adragos signs agreement with Towa Pharmaceutical to supply off-patent medicines

Adragos signs agreement with Towa Pharmaceutical to supply off-patent medicines

Adragos Pharma Kawagoe KK has announced the signing of an agreement with Towa Pharmaceutical Co., Ltd, to establish a strategic collaboration aimed at ensuring the stable supply of off-patent pharmaceuticals
Manufacturing
SCHOTT Pharma and SHL Medical enhance home-based large-volume injections for patients

SCHOTT Pharma and SHL Medical enhance home-based large-volume injections for patients

SCHOTT Pharma and SHL Medical have joined forces to introduce the first large-volume cartridge in an autoinjector
Regulatory
Sanofi expands vaccine manufacturing in Abu Dhabi as NICE backs its diabetes therapy

Sanofi expands vaccine manufacturing in Abu Dhabi as NICE backs its diabetes therapy

Sanofi advances on two fronts: a new Abu Dhabi vaccine innovation centre with AI and mRNA capabilities and UK NICE backing for teplizumab, the first disease-modifying treatment for type 1 diabetes
Research & Development
PharmNovo reports broader therapeutic potential for PN6047

PharmNovo reports broader therapeutic potential for PN6047

PharmNovo AB has announced new preclinical findings supporting the potential of PN6047 in migraine and opioid withdrawal syndrome. The findings were generated through the company's NIDA-funded collaboration with researchers at Washington University School of Medicine
Sustainability
Haier Biomedical introduces higher capacity benchtop centrifuge with rapid pre-cooling

Haier Biomedical introduces higher capacity benchtop centrifuge with rapid pre-cooling

Haier Biomedical – a trusted partner in reliable laboratory equipment – has introduced the LX-155T750R, its latest high-speed, benchtop centrifuge featuring ECO fastBlast pre-cooling technology
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development
Neuropsychiatric medicine reaches an inflexion point: regulation, science and the road to commercial reality

Neuropsychiatric medicine reaches an inflexion point: regulation, science and the road to commercial reality

Shaped by accelerating regulatory support, expanding clinical evidence and growing institutional acceptance, psychedelic medicine is entering a pivotal phase, reports Joel Latham, Chief Executive Officer, President and Director at Incannex Healthcare Inc.
Subscribe now